Literature DB >> 10571006

Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the non-lysosomal beta-galactosidase-like protein.

J W Callahan1.   

Abstract

GM1 gangliosidosis and Morquio B disease are distinct disorders both clinically and biochemically yet they arise from the same beta-galactosidase enzyme deficiency. On the other hand, galactosialidosis and sialidosis share common clinical and biochemical features, yet they arise from two separate enzyme deficiencies, namely, protective protein/cathepsin A and neuraminidase, respectively. However distinct, in practice these disorders overlap both clinically and biochemically so that easy discrimination between them is sometimes difficult. The principle reason for this may be found in the fact that these three enzymes form a unique complex in lysosomes that is required for their stability and posttranslational processing. In this review, I focus mainly on the primary and secondary beta-galactosidase deficiency states and offer some hypotheses to account for differences between GM1 gangliosidosis and Morquio B disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571006     DOI: 10.1016/s0925-4439(99)00075-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

1.  Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

Authors:  S Zhang; R Bagshaw; W Hilson; Y Oho; A Hinek; J T Clarke; J W Callahan
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Expression, purification, crystallization and preliminary X-ray crystallographic analysis of human β-galactosidase.

Authors:  Kimihito Usui; Umeharu Ohto; Toshinari Ochi; Toshiyuki Shimizu; Yoshinori Satow
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-12-24

Review 3.  Lysosomal membrane proteomics and biogenesis of lysosomes.

Authors:  Richard D Bagshaw; Don J Mahuran; John W Callahan
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

4.  β-Galactosidosis in Patient with Intermediate GM1 and MBD Phenotype.

Authors:  Tereza Moore; Jonathan A Bernstein; Sylvie Casson-Parkin; Tina M Cowan
Journal:  JIMD Rep       Date:  2012-04-22

Review 5.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

6.  Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.

Authors:  Katrin M Fantur; Tanja M Wrodnigg; Arnold E Stütz; Bettina M Pabst; Eduard Paschke
Journal:  J Inherit Metab Dis       Date:  2011-10-28       Impact factor: 4.982

7.  SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases.

Authors:  L Ou; M J Przybilla; C B Whitley
Journal:  Clin Genet       Date:  2018-03-05       Impact factor: 4.438

8.  Elastin peptides signaling relies on neuraminidase-1-dependent lactosylceramide generation.

Authors:  Anthony Rusciani; Laurent Duca; Hervé Sartelet; Aurore Chatron-Colliet; Hélène Bobichon; Dominique Ploton; Richard Le Naour; Sébastien Blaise; Laurent Martiny; Laurent Debelle
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.

Authors:  Douglas R Martin; Brigitte A Rigat; Polly Foureman; G S Varadarajan; Misako Hwang; Barbara K Krum; Bruce F Smith; John W Callahan; Don J Mahuran; Henry J Baker
Journal:  Mol Genet Metab       Date:  2008-03-18       Impact factor: 4.797

10.  A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.

Authors:  Tomoko Takai; Katsumi Higaki; Matilde Aguilar-Moncayo; Teresa Mena-Barragán; Yuki Hirano; Kei Yura; Liang Yu; Haruaki Ninomiya; M Isabel García-Moreno; Yasubumi Sakakibara; Kousaku Ohno; Eiji Nanba; Carmen Ortiz Mellet; José M García Fernández; Yoshiyuki Suzuki
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.